Skip to main content
. 2014 Jun 14;3(4):1010–1024. doi: 10.1002/cam4.269

Figure 5.

Figure 5

Kaplan–Meier survival curves for CNS versus non-CNS IVL patients. Patients with CNS IVL had significantly shorter survival than non-CNS patients in (A) time from initial presentation of symptoms to death, (C) time from diagnosis to death, and (F) time from treatment to death, but not (G) time from treatment to first recurrence. (B) The median survival of CNS IVL patients diagnosed postmortem was significantly shorter than those diagnosed premortem, 3.5 (range 0.1–30.0, n = 150) versus 17.0 (range 0.5–71.1, n = 98) months, respectively (P = 0.0001). (D) The difference between CNS and non-CNS IVL remains significant in each successive decade for median time from initial presentation of symptoms to death in the 1960–1980s (CNS versus non-CNS: 4.1 [range 1.0–24.0, n = 35] versus 12.0 [range 0.3–33.0, n = 23] months [P = 0.0005]), 1990s (CNS versus non-CNS: 6.0 [range 0.1–71.0, n = 91] versus 12.0 [range 0.4–87.0, n = 75] months [P = 0.0002]), and 2000s (CNS versus non-CNS: 9.0 [range 0.1–58.0, n = 122] versus 14.0 [range 0.1–110.0, n = 206] months [P = 0.0087]). For CNS IVL, the difference was also significant between decades 1960–1980s and 1990s (P = 0.0507) and 1960–1990s and 2000s (P = 0.0009). (E) For median time from diagnosis to death, the difference between CNS and non-CNS IVL remains significant in each successive decade in the 1960–1980s (CNS versus non-CNS: 6.0 [range 0.9–14.0, n = 6] versus 15.0 [range 0.5–42.0, n = 14] months [P = 0.0184]) and 1990s (CNS versus non-CNS: 8.0 [range 0.1–71.0, n = 43] versus 17.0 [range 0.1–96.0, n = 58] months [P = 0.0279]), and near significance in 2000s 18.0 [range 0.3–84.0, n = 98] versus 20.0 [range 0.1–165.0, n = 221] months [P = 0.0515]. For CNS IVL, the difference was only significant between decades 1960–1990s versus 2000s (P = 0.0462). (H) For time from treatment to death, only the decade 2000s was significant for CNS versus non-CNS IVL: 20.0 (range 0.3–84.0, n = 82) versus 30.0 (range 0.1–165.0, n = 171) months (P = 0.0196) but not significant for CNS IVL's in successive decades. (I) For time from treatment to first recurrence, no statistical difference was found in survival in CNS versus non-CNS, as well as CNS IVL's, in each successive decades. IVL, intravascular lymphomatosis; CNS, central nervous system.